Krystal Biotech, Inc. (KRYS) Stock Analysis
Temp Headwind edge
Healthcare · Biotechnology
Wait for pullback to $271.04. Weak momentum — blocks BUY_NOW at $298.47. Engine's entry $271.04 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Expensive valuation.
Krystal Biotech is a commercial-stage biotech that develops, manufactures, and commercializes HSV-1-based gene therapies; its lead product VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB), with $730.3M in cumulative net product revenue... Read more
Wait for pullback to $271.04. Weak momentum — blocks BUY_NOW at $298.47. Engine's entry $271.04 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Expensive valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.55, quality 7.9/10, growth 10.0/10). Score 6.1/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Krystal Biotech, Inc.
Latest news
- Krystal Biotech, Inc. (KRYS) earnings expected to grow: What to know ahead of next week's release - MSN — MSN positive
- Nestlé Joins the Microbiome Therapeutics Innovation Group (MTIG); Krys Araujo‑Torres, MD, MPP to Represent Company - PR — PR Newswire neutral
- Earnings Preview: KRYS to Report Financial Results Pre-market on May 04 - 富途牛牛 — 富途牛牛 neutral
- Krystal Biotech stock hits all-time high at 315.68 USD - Investing.com — Investing.com positive
- Krystal Biotech, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:KRYS) 2026-05-06 - Seeking Alpha — Seeking Alpha neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $271.04. Weak momentum — blocks BUY_NOW at $298.47. Engine's entry $271.04 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Expensive valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.55, quality 7.9/10, growth 10.0/10). Target $313.09 (+4.9%), stop $252.07 (−18.4%), Setup A.R:R 2.2:1. Score 6.1/10, moderate confidence.
Take-profit target: $313.09 (+15.5% upside). Target $313.09 (+4.9%), stop $252.07 (−18.4%), Setup A.R:R 2.2:1. Stop-loss: $252.07.
Analyst target reached - limited upside remaining; Expensive valuation; Negative momentum.
Krystal Biotech, Inc. trades at a P/E of 39.3 (forward 29.1). TrendMatrix value score: 4.0/10. Verdict: Buy (Wait for Entry).
18 analysts cover KRYS with a consensus score of 4.3/5. Average price target: $323.
What does Krystal Biotech, Inc. do?Krystal Biotech is a commercial-stage biotech that develops, manufactures, and commercializes HSV-1-based gene...
Krystal Biotech is a commercial-stage biotech that develops, manufactures, and commercializes HSV-1-based gene therapies; its lead product VYJUVEK is approved in the US, EU, and Japan for dystrophic epidermolysis bullosa (DEB), with $730.3M in cumulative net product revenue since 2023 launch. Pipeline includes KB407 (CF, Phase 1) and KB408 (AATD, Phase 1), supported by two in-house CGMP manufacturing facilities.